Radionuclide Imaging in Stage B Heart Failure

Heart Failure Clinics

Volumn 8, Issue 2, 2012, Pages 191-206

  Janardhanan, Rajesh ^a   Beller, George A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Asymptomatic left ventricular dysfunction; Ischemic cardiomyopathy; Positron emission tomography; Radionuclide imaging; Single photon emission computed tomography; Stage B heart failure; Viability

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 14 FLURO 6 THIA HEPTADECANOIC ACID F 18; 15 (4 IODOPHENYL) 3 METHLYPENTADECANOIC I 123; ACETIC ACID C 11; DOBUTAMINE; FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITROGEN 13; OXYGEN 15; RADIOISOTOPE; RUBIDIUM 82; TECHNETIUM 99M; THALLIUM 201; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; AUTONOMIC INNERVATION; CARDIAC IMAGING; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOLOGY; DRUG DISTRIBUTION; DRUG STORAGE; DRUG UPTAKE; HEART FAILURE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE PERFUSION; HUMAN; ISCHEMIC CARDIOMYOPATHY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVASCULARIZATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

3-IODOBENZYLGUANIDINE; ASYMPTOMATIC DISEASES; CARDIOMYOPATHIES; CHRONIC DISEASE; CORONARY ARTERY DISEASE; GLUCOSE; HEART; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIONUCLIDE VENTRICULOGRAPHY; RADIOPHARMACEUTICALS; SARCOIDOSIS; TISSUE SURVIVAL; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84858124158     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.11.004     Document Type: Review

References (85)

1. Ghali J.K., Cooper R., Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalence. Arch Intern Med 1990, 150(4):769-773.
2. Gheorghiade M., Bonow R.O. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998, 97(3):282-289.
3. Goldberg L.R., Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation 2006, 113(24):2851-2860.
4. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112(12):e154-e235.
5. Frigerio M., Oliva F., Turazza F.M., et al. Prevention and management of chronic heart failure in management of asymptomatic patients. Am J Cardiol 2003, 91(9A):4F-9F.
6. Wang T.J., Evans J.C., Benjamin E.J., et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003, 108(8):977-982.
7. Germano G., Kavanagh P.B., Slomka P.J., et al. Quantitation in gated perfusion SPECT imaging: the Cedars-Sinai approach. J Nucl Cardiol 2007, 14(4):433-454.
8. Hyun I.Y., Kwan J., Park K.S., et al. Reproducibility of Tl-201 and Tc-99m sestamibi gated myocardial perfusion SPECT measurement of myocardial function. J Nucl Cardiol 2001, 8(2):182-187.
9. Johnson L.L., Verdesca S.A., Aude W.Y., et al. Postischemic stunning can affect left ventricular ejection fraction and regional wall motion on post-stress gated sestamibi tomograms. J Am Coll Cardiol 1997, 30(7):1641-1648.
10. He J., Ogden L.G., Bazzano L.A., et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001, 161(7):996-1002.
11. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992, 327(10):685-691.
12. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362(9377):7-13.
13. Klocke F.J., Baird M.G., Lorell B.H., et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 2003, 42(7):1318-1333.
14. Udelson J.E., Shafer C.D., Carrio I. Radionuclide imaging in heart failure: assessing etiology and outcomes and implications for management. J Nucl Cardiol 2002, 9(Suppl 5):40S-52S.
15. Danias P.G., Papaioannou G.I., Ahlberg A.W., et al. Usefulness of electrocardiographic-gated stress technetium-99m sestamibi single-photon emission computed tomography to differentiate ischemic from nonischemic cardiomyopathy. Am J Cardiol 2004, 94(1):14-19.
16. Soman P., Lahiri A., Mieres J.H., et al. Etiology and pathophysiology of new-onset heart failure: evaluation by myocardial perfusion imaging. J Nucl Cardiol 2009, 16(1):82-91.
17. Wu Y.W., Yen R.F., Chieng P.U., et al. Tl-201 myocardial SPECT in differentiation of ischemic from nonischemic dilated cardiomyopathy in patients with left ventricular dysfunction. J Nucl Cardiol 2003, 10(4):369-374.
18. Doi Y.L., Chikamori T., Tukata J., et al. Prognostic value of thallium-201 perfusion defects in idiopathic dilated cardiomyopathy. Am J Cardiol 1991, 67(2):188-193.
19. Soman P., Dave D.M., Udelson J.E., et al. Vascular endothelial dysfunction is associated with reversible myocardial perfusion defects in the absence of obstructive coronary artery disease. J Nucl Cardiol 2006, 13(6):756-760.
20. Heller G.V., Links J., Bateman T.M., et al. American Society of Nuclear Cardiology and Society of Nuclear Medicine joint position statement: attenuation correction of myocardial perfusion SPECT scintigraphy. J Nucl Cardiol 2004, 11(2):229-230.
21. Naya M., Di Carli M.F. Myocardial perfusion PET/CT to evaluate known and suspected coronary artery disease. Q J Nucl Med Mol Imaging 2010, 54(2):145-156.
22. Berman D.S., Shaw L.J., Min J.K., et al. SPECT/PET myocardial perfusion imaging versus coronary CT angiography in patients with known or suspected CAD. Q J Nucl Med Mol Imaging 2010, 54(2):177-200.
23. Gaemperli O., Kaufmann P.A. Multimodality cardiac imaging. J Nucl Cardiol 2010, 17(1):4-7.
24. Knuuti J., Kajander S., Maki M., et al. Quantification of myocardial blood flow will reform the detection of CAD. J Nucl Cardiol 2009, 16(4):497-506.
25. Muhlbaier L.H., Pryor D.B., Rankin J.S., et al. Observational comparison of event-free survival with medical and surgical therapy in patients with coronary artery disease. 20 years of follow-up. Circulation 1992, 86(Suppl 5):II198-II204.
26. Di Carli M.F., Asgarzadie F., Schelbert H.R., et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995, 92(12):3436-3444.
27. Marwick T.H., Zuchowski C., Lauer M.S., et al. Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability. J Am Coll Cardiol 1999, 33(3):750-758.
28. Bax J.J., Poldermans D., Elhendy A., et al. Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. J Am Coll Cardiol 1999, 34(1):163-169.
29. Bax J.J., Wijns W., Cornel J.H., et al. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 1997, 30(6):1451-1460.
30. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000, 343(20):1445-1453.
31. Meluzin J., Cigarroa C.G., Brickner M.E., et al. Dobutamine echocardiography in predicting improvement in global left ventricular systolic function after coronary bypass or angioplasty in patients with healed myocardial infarcts. Am J Cardiol 1995, 76(12):877-880.
32. Senior R., Kaul S., Raval U., et al. Impact of revascularization and myocardial viability determined by nitrate-enhanced Tc-99m sestamibi and Tl-201 imaging on mortality and functional outcome in ischemic cardiomyopathy. J Nucl Cardiol 2002, 9(5):454-462.
33. Allman K.C., Shaw L.J., Hachamovitch R., et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002, 39(7):1151-1158.
34. Pagley P.R., Beller G.A., Watson D.D., et al. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation 1997, 96(3):793-800.
35. Senior R., Lahiri A., Kaul S. Effect of revascularization on left ventricular remodeling in patients with heart failure from severe chronic ischemic left ventricular dysfunction. Am J Cardiol 2001, 88(6):624-629.
36. Bonow R.O. Identification of viable myocardium. Circulation 1996, 94(11):2674-2680.
37. Samady H., Elefteriades J.A., Abbott B.G., et al. Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome. Circulation 1999, 100(12):1298-1304.
38. Myers J.H., Stirling M.C., Choy M., et al. Direct measurement of inner and outer wall thickening dynamics with epicardial echocardiography. Circulation 1986, 74(1):164-172.
39. Lieberman A.N., Weiss J.L., Jugdutt B.I., et al. Two-dimensional echocardiography and infarct size: relationship of regional wall motion and thickening to the extent of myocardial infarction in the dog. Circulation 1981, 63(4):739-746.
40. Kaul S. There may be more to myocardial viability than meets the eye. Circulation 1995, 92(10):2790-2793.
41. Schinkel A.F., Poldermans D., Elhendy A., et al. Assessment of myocardial viability in patients with heart failure. J Nucl Med 2007, 48(7):1135-1146.
42. Schinkel A.F., Bax J.J., Delgado V., et al. Clinical relevance of hibernating myocardium in ischemic left ventricular dysfunction. Am J Med 2010, 123(11):978-986.
43. Pohost G.M., Zir L.M., Moore R.H., et al. Differentiation of transiently ischemic from infarcted myocardium by serial imaging after a single dose of thallium-201. Circulation 1977, 55(2):294-302.
44. Bonow R.O., Dilsizian V. Thallium-201 and technetium-99m-sestamibi for assessing viable myocardium. J Nucl Med 1992, 33(5):815-818.
45. Udelson J.E., Coleman P.S., Metherall J., et al. Predicting recovery of severe regional ventricular dysfunction. Comparison of resting scintigraphy with 201Tl and 99mTc-sestamibi. Circulation 1994, 89(6):2552-2561.
46. Sciagra R., Bisi G., Santoro G.M., et al. Comparison of baseline-nitrate technetium-99m sestamibi with rest-redistribution thallium-201 tomography in detecting viable hibernating myocardium and predicting postrevascularization recovery. J Am Coll Cardiol 1997, 30(2):384-391.
47. Auerbach M.A., Schoder H., Hoh C., et al. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation 1999, 99(22):2921-2926.
48. Cleland J.G., Pennell D.J., Ray S.G., et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 2003, 362(9377):14-21.
49. Camici P.G., Wijns W., Borgers M., et al. Pathophysiological mechanisms of chronic reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium). Circulation 1997, 96(9):3205-3214.
50. Wijns W., Vatner S.F., Camici P.G. Hibernating myocardium. N Engl J Med 1998, 339(3):173-181.
51. 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993, 87(5):1630-1641.
52. Camici P.G., Prasad S.K., Rimoldi O.E. Stunning, hibernation, and assessment of myocardial viability. Circulation 2008, 117(1):103-114.
53. 18FDG DISA SPECT with PET for the detection of viability in patients with coronary artery disease and left ventricular dysfunction. Eur J Nucl Med Mol Imaging 2005, 32(8):972-979.
54. Chareonthaitawee P., Christian T.F., Hirose K., et al. Relation of initial infarct size to extent of left ventricular remodeling in the year after acute myocardial infarction. J Am Coll Cardiol 1995, 25(3):567-573.
55. Christian T.F., Behrenbeck T., Gersh B.J., et al. Relation of left ventricular volume and function over one year after acute myocardial infarction to infarct size determined by technetium-99m sestamibi. Am J Cardiol 1991, 68(1):21-26.
56. Christian T.F., Behrenbeck T., Pellikka P.A., et al. Mismatch of left ventricular function and infarct size demonstrated by technetium-99m isonitrile imaging after reperfusion therapy for acute myocardial infarction: identification of myocardial stunning and hyperkinesia. J Am Coll Cardiol 1990, 16(7):1632-1638.
57. Rahimtoola S.H. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985, 72(6 Pt 2):V123-V135.
58. Elefteriades J.A., Tolis G., Levi E., et al. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol 1993, 22(5):1411-1417.
59. Rizzello V., Poldermans D., Biagini E., et al. Prognosis of patients with ischaemic cardiomyopathy after coronary revascularisation: relation to viability and improvement in left ventricular ejection fraction. Heart 2009, 95(15):1273-1277.
60. Eitzman D., al-Aouar Z., Kanter H.L., et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992, 20(3):559-565.
61. Di Carli M.F., Davidson M., Little R., et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994, 73(8):527-533.
62. Stevenson W.G., Stevenson L.W., Middlekauff H.R., et al. Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol 1995, 26(6):1417-1423.
63. Siebelink H.M., Blanksma P.K., Crijns H.J., et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol 2001, 37(1):81-88.
64. Schinkel A.F., Poldermans D., Rizzello V., et al. Why do patients with ischemic cardiomyopathy and a substantial amount of viable myocardium not always recover in function after revascularization?. J Thorac Cardiovasc Surg 2004, 127(2):385-390.
65. Soman P. Gated SPECT myocardial perfusion scintigraphy: a multi-faceted tool for the evaluation of heart failure. J Nucl Cardiol 2009, 16(2):173-175.
66. Candell-Riera J., Romero-Farina G., Aguade-Bruix S., et al. Prognostic value of myocardial perfusion-gated SPECT in patients with ischemic cardiomyopathy. J Nucl Cardiol 2009, 16(2):212-221.
67. Sharir T. Role of regional myocardial dysfunction by gated myocardial perfusion SPECT in the prognostic evaluation of patients with coronary artery disease. J Nucl Cardiol 2005, 12(1):5-8.
68. Curtis J.P., Sokol S.I., Wang Y., et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 2003, 42(4):736-742.
69. Felker G.M., Shaw L.K., O'Connor C.M. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002, 39(2):210-218.
70. Flotats A., Carrio I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol 2004, 11(5):587-602.
71. Carrio I. Cardiac neurotransmission imaging. J Nucl Med 2001, 42(7):1062-1076.
72. Bengel F.M., Schwaiger M. Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol 2004, 11(5):603-616.
73. Kawai Y., Tsukamoto E., Nozaki Y., et al. Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol 2001, 38(7):1888-1894.
74. Buxton D.B., Schwaiger M., Nguyen A., et al. Radiolabeled acetate as a tracer of myocardial tricarboxylic acid cycle flux. Circ Res 1988, 63(3):628-634.
75. 11C-acetate PET after long-term cardiac resynchronization therapy. J Nucl Med 2006, 47(3):378-383.
76. Wallhaus T.R., Taylor M., DeGrado T.R., et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001, 103(20):2441-2446.
77. Botvinick E.H. Scintigraphic blood pool and phase image analysis: the optimal tool for the evaluation of resynchronization therapy. J Nucl Cardiol 2003, 10(4):424-428.
78. Vilain D., Daou D., Casset-Senon D., et al. Optimal 3-dimensional method for right and left ventricular Fourier phase analysis in electrocardiography-gated blood-pool SPECT. J Nucl Cardiol 2001, 8(3):371-378.
79. Chen J., Garcia E.V., Folks R.D., et al. Onset of left ventricular mechanical contraction as determined by phase analysis of ECG-gated myocardial perfusion SPECT imaging: development of a diagnostic tool for assessment of cardiac mechanical dyssynchrony. J Nucl Cardiol 2005, 12(6):687-695.
80. Marsan N.A., Henneman M.M., Chen J., et al. Left ventricular dyssynchrony assessed by two three-dimensional imaging modalities: phase analysis of gated myocardial perfusion SPECT and tri-plane tissue Doppler imaging. Eur J Nucl Med Mol Imaging 2008, 35(1):166-173.
81. Ji S.Y., Travin M.I. Radionuclide imaging of cardiac autonomic innervation. J Nucl Cardiol 2010, 17(4):655-666.
82. Carrio I., Cowie M.R., Yamazaki J., et al. Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging 2010, 3(1):92-100.
83. Jacobson A.F., Senior R., Cerqueira M.D., et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010, 55(20):2212-2221.
84. Carrio I., Flotats A. Cardiac sympathetic imaging with mIBG: a tool for better assessment of the diabetic heart. Eur J Nucl Med Mol Imaging 2010, 37(9):1696-1697.
85. 123I-metaiodobenzylguanidine myocardial scintigraphy and heart rate variability. Eur J Nucl Med Mol Imaging 2010, 37(9):1698-1705.